{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:04:37Z","timestamp":1760551477156,"version":"3.40.5"},"reference-count":40,"publisher":"Galenos Yayinevi","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjps"],"published-print":{"date-parts":[[2022,2,25]]},"DOI":"10.4274\/tjps.galenos.2021.47417","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T14:08:31Z","timestamp":1622210911000},"page":"63-69","source":"Crossref","is-referenced-by-count":2,"title":["Novel Indole Derivative as the First P-glycoprotein Inhibitor from the Skin of Indian Toad <i>(Bufo melanostictus)<\/i>"],"prefix":"10.4274","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7145-1699","authenticated-orcid":false,"given":"Prasad","family":"NEERATI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8546-4741","authenticated-orcid":false,"given":"Sangeethkumar","family":"MUNIGADAPA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"ref0","unstructured":"1. Zhang Y. Why do we study animal toxins? Dongwuxue Yanjiu. 2015;36:183-222."},{"key":"ref1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4331\/wjbc.v6.i2.28","article-title":"Animal venom studies: Current benefits and future developments","volume":"6","author":"Utkin","year":"2015","unstructured":"2. Utkin YN. Animal venom studies: Current benefits and future developments. World J Biol Chem. 2015;6:28-33.","journal-title":"World J Biol Chem"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/toxins10030126","article-title":"Toxins in drug discovery and pharmacology","volume":"10","author":"Peigneur","year":"2018","unstructured":"3. Peigneur S, Tytgat J. Toxins in drug discovery and pharmacology. Toxins (Basel). 2018;10:126.","journal-title":"Toxins (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"312684","DOI":"10.1155\/2014\/312684","article-title":"Toad glandular secretions and skin extractions as anti-inflammatory and anticancer agents","volume":"2014","author":"Qi","year":"2014","unstructured":"4. Qi J, Tan CK, Hashimi SM, Zulfiker AH, Good D, Wei MQ. Toad glandular secretions and skin extractions as anti-inflammatory and anticancer agents. Evid Based Complement Alternat Med. 2014;2014:312684.","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Urban MC, Phillips BL, Skelly DK, Shine R. A toad more traveled: the heterogeneous invasion dynamics of cane toads in Australia. Am Nat. 2008;171:E134-E148.","DOI":"10.1086\/527494"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Garg A, Hippargi R, Gandhare A. Toad skin-secretions: potent source of pharmacologically and therapeutically significant compounds. Int J Pharmacol. 2007;5:17.","DOI":"10.5580\/18b6"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/aja.1001710108","article-title":"Morphology of the exocrine glands of the frog skin","volume":"171","author":"JW","year":"1984","unstructured":"7. Mills JW, Prum BE. Morphology of the exocrine glands of the frog skin. Am J Anat. 1984;171:91-106.","journal-title":"Am J Anat"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1038\/s41598-018-22005-5","article-title":"Skin gland concentrations adapted to different evolutionary pressures in the head and posterior regions of the caecilian siphonops annulatus","volume":"1","author":"Jared","year":"2018","unstructured":"8. Jared C, Mailho-Fontana PL, Marques-Porto R, Sciani JM, Pimenta DC, Brodie Jr. ED, Antoniazzi MM. Skin gland concentrations adapted to different evolutionary pressures in the head and posterior regions of the caecilian siphonops annulatus. Sci Rep. 2018;1:3576.","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Toledo RC, Jared C. Cutaneous granular glands and amphibian venom. Comp Biochem Physiol. 1995;1-29.","DOI":"10.1016\/0300-9629(95)98515-I"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/molecules24010086","article-title":"Comparative analysis of hydrophilic ingredients in toad skin and toad venom using the UHPLC-HR-MS\/MS and UPLC-QqQ-MS\/MS methods together with the anti-inflammatory evaluation of indolealkylamines","volume":"24","author":"Zhang","year":"2018","unstructured":"10. Zhang Y, Yuan B, Takagi N, Wang H, Zhou Y, Si N, Yang J, Wei X, Zhao H, Bian B. Comparative analysis of hydrophilic ingredients in toad skin and toad venom using the UHPLC-HR-MS\/MS and UPLC-QqQ-MS\/MS methods together with the anti-inflammatory evaluation of indolealkylamines. Molecules. 2018;24:86.","journal-title":"Molecules"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Ramana KV, Singhal SS, Reddy AB. Therapeutic potential of natural pharmacological agents in the treatment of human diseases. BioMed Res Int. 2014;573452.","DOI":"10.1155\/2014\/573452"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jep.2016.03.062","article-title":"Chemical profiling and cytotoxicity assay of bufadienolides in toad venom and toad skin","volume":"187","author":"Meng","year":"2016","unstructured":"12. Meng Q, Yau LF, Lu JG, Wu ZZ, Zhang BX, Wang JR, Jiang ZH. Chemical profiling and cytotoxicity assay of bufadienolides in toad venom and toad skin. J Ethnopharmacol. 2016;187:74-82.","journal-title":"J Ethnopharmacol"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol. 1997;160:161-175.","DOI":"10.1007\/s002329900305"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics: clinical implications","volume":"42","author":"JH","year":"2003","unstructured":"14. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42:59-98.","journal-title":"Clin Pharmacokinet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"484963","DOI":"10.1155\/2015\/484963","article-title":"Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy","volume":"2015","author":"Hoosain","year":"2015","unstructured":"15. Hoosain FG, Choonara YE, Tomar LK, Kumar P, Tyagi C, du Toit LC, Pillay V. Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy. Biomed Res Int. 2015;2015:484963.","journal-title":"Biomed Res Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4137\/DTI.S12519","article-title":"P-glycoprotein inhibition for optimal drug delivery","volume":"7","author":"Amin","year":"2013","unstructured":"16. Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights. 2013;7:27-34.","journal-title":"Drug Target Insights"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3748\/wjg.v6.i1.134","article-title":"Overexpression of P-glycoprotein in hepatocellular carcinoma and its clinical implication","volume":"6","author":"Kong","year":"2000","unstructured":"17. Kong XB, Yang ZK, Liang LJ, Huang JF, Lin HL. Overexpression of P-glycoprotein in hepatocellular carcinoma and its clinical implication. World J Gastroenterol. 2000;6:134-135.","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cellsig.2017.01.001","article-title":"Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR","volume":"31","author":"Kim","year":"2017","unstructured":"18. Kim SW, Md Hasanuzzaman, Cho M, Kim NH, Choi HY, Han JW, Park HJ, Oh JW, Shin JG. Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR. Cell Signal. 2017;31:124-134.","journal-title":"Cell Signal"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1517\/17425251003610640","article-title":"P-glycoprotein related drug interactions: clinical importance and a consideration of disease states","volume":"6","author":"Lee","year":"2010","unstructured":"19. Lee CA, Cook JA, Reyner EL, Smith DA. P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol. 2010;6:603-619.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Glaeser H. Importance of P-glycoprotein for drug-drug interactions. Handb Exp Pharmacol. 2011;285-297.","DOI":"10.1007\/978-3-642-14541-4_7"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/13543776.2019.1618273","article-title":"An updated patent review on P-glycoprotein inhibitors (2011-2018)","volume":"29","author":"Leopoldo","year":"2019","unstructured":"21. Leopoldo M, Nardulli P, Contino M, Leonetti F, Luurtsema G, Colabufo NA. An updated patent review on P-glycoprotein inhibitors (2011-2018). Expert Opin Ther Pat. 2019;29:455-461.","journal-title":"Expert Opin Ther Pat"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2174\/15680096113139990076","article-title":"P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives","volume":"13","author":"Binkhathlan","year":"2013","unstructured":"22. Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013;13:326-346.","journal-title":"Curr Cancer Drug Targets"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2174\/1389200219666181003142036","article-title":"Drug-drug interactions of P-gp substrates unrelated to CYP metabolism","volume":"20","author":"Akamine","year":"2019","unstructured":"23. Akamine Y, Yasui-Furukori N, Uno T. Drug-drug interactions of P-gp substrates unrelated to CYP metabolism. Curr Drug Metab. 2019;20:124-129.","journal-title":"Curr Drug Metab"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"108675","DOI":"10.1016\/j.abb.2020.108675","article-title":"Efflux mechanism and pathway of verapamil pumping by human P-glycoprotein","volume":"696","author":"Wang","year":"2020","unstructured":"24. Wang L, Sun Y. Efflux mechanism and pathway of verapamil pumping by human P-glycoprotein. Arch Biochem Biophys. 2020;696:108675.","journal-title":"Arch Biochem Biophys"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Sasidharan S, Chen Y, Saravanan D, Sundram KM, Yoga Latha L. Extraction, isolation and characterization of bioactive compounds from plants' extracts. Afr J Tradit Complement Altern Med. 2011;8:1-10.","DOI":"10.4314\/ajtcam.v8i1.60483"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/jpbs.JPBS_175_19","article-title":"Preparation of Medicinal Plants: Basic extraction and fractionation procedures for experimental purposes","volume":"12","author":"AR","year":"2020","unstructured":"26. Abubakar AR, Haque M. Preparation of Medicinal Plants: Basic extraction and fractionation procedures for experimental purposes. J Pharm Bioallied Sci. 2020;12:1-10.","journal-title":"J Pharm Bioallied Sci"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Ottesen JL, Weber A, G\u00fcrtler H, Mikkelsen LF. New housing conditions: improving the welfare of experimental animals. Altern Lab Anim. 2004;(Suppl 1B):397-404.","DOI":"10.1177\/026119290403201s65"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.fct.2012.11.023","article-title":"Application of OECD Guideline 423 in assessing the acute oral toxicity of moniliformin","volume":"53","author":"Jonsson","year":"2013","unstructured":"28. Jonsson M, Jestoi M, Nathanail AV, Kokkonen UM, Anttila M, Koivisto P, Karhunen P, Peltonen K. Application of OECD Guideline 423 in assessing the acute oral toxicity of moniliformin. Food Chem Toxicol. 2013;53:27-32.","journal-title":"Food Chem Toxicol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/BF03189357","article-title":"An improved everted gut sac as a simple and accurate technique to measure paracellular transport across the small intestine","volume":"23","author":"Barthe","year":"1998","unstructured":"29. Barthe L, Woodley JF, Kenworthy S, Houin G. An improved everted gut sac as a simple and accurate technique to measure paracellular transport across the small intestine. Eur J Drug Metab Pharmacokinet. 1998;23:313-323.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10928-008-9086-4","article-title":"A general approach to the apparent permeability index","volume":"35","author":"Palumbo","year":"2008","unstructured":"30. Palumbo P, Picchini U, Beck B, van Gelder J, Delbar N, DeGaetano A. A general approach to the apparent permeability index. J Pharmacokinet Pharmacodyn. 2008;35:235-248.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Zou W, Yang Y, Gu Y, Zhu P, Zhang M, Cheng Z, Liu X, Yu Y, Peng X. Repeated blood collection from tail vein of non-anesthetized rats with a vacuum blood collection system. J Vis Exp. 2017:55852.","DOI":"10.3791\/55852"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/clinchem\/26.12.1760a","article-title":"Modified acetonitrile protein-precipitation method of sample preparation for drug assay by liquid chromatography","volume":"26","author":"JC","year":"1980","unstructured":"32. Mathies JC, Austin MA. Modified acetonitrile protein-precipitation method of sample preparation for drug assay by liquid chromatography. Clin Chem. 1980;26:1760.","journal-title":"Clin Chem"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12906-017-1713-4","article-title":"Rhizome ethanolic extract","volume":"17","author":"Amuamuta","year":"2017","unstructured":"33. Amuamuta A, Plengsuriyakarn T, Na-Bangchang K. Anticholangiocarcinoma activity and toxicity of the Kaempferia galanga Linn. Rhizome ethanolic extract. BMC Complement Altern Med. 2017;17:213.","journal-title":"BMC Complement Altern Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1007\/s00248-017-0997-8","article-title":"Identification of bufadienolides from the boreal toad, anaxyrus boreas, active against a fungal pathogen","volume":"74","author":"Barnhart","year":"2017","unstructured":"34. Barnhart K, Forman ME, Umile TP, Kueneman J, McKenzie V, Salinas I, Minbiole KPC, Woodhams DC. Identification of bufadienolides from the boreal toad, anaxyrus boreas, active against a fungal pathogen. Microb Ecol. 2017;74:990-1000.","journal-title":"Microb Ecol"},{"key":"ref34","unstructured":"35. Manika D, Auddy B, Gomes A. Pharmacological study of the toad skin extract on experimental animals. Indian J Pharmacol. 1996;2:72-76."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ptr.1173","article-title":"Screening of Tanzanian plant extracts for their potential inhibitory effect on P-glycoprotein mediated efflux","volume":"17","author":"Deferme","year":"2003","unstructured":"36. Deferme S, Kamuhabwa A, Nshimo C, de Witte P, Augustijns P. Screening of Tanzanian plant extracts for their potential inhibitory effect on P-glycoprotein mediated efflux. Phytother Res. 2003;17:459-464.","journal-title":"Phytother Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1345\/aph.1E068","article-title":"Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy","volume":"38","author":"Summers","year":"2004","unstructured":"37. Summers MA, Moore JL, McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother. 2004;38:1631-1634.","journal-title":"Ann Pharmacother"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3892\/or.2017.5410","article-title":"Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin","volume":"37","author":"Yuan","year":"2017","unstructured":"38. Yuan Z, Shi X, Qiu Y, Jia T, Yuan X, Zou Y, Liu C, Yu H, Yuan Y, He X, Xu K, Yin P. Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin. Oncol Rep. 2017;37:1815-1825.","journal-title":"Oncol Rep"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.18433\/J3MK72","article-title":"Enhanced oral bioavailability of domperidone with piperine in male wistar rats: involvement of CYP3A1 and P-gp inhibition","volume":"20","author":"BL","year":"2017","unstructured":"39. Athukuri BL, Neerati P. Enhanced oral bioavailability of domperidone with piperine in male wistar rats: involvement of CYP3A1 and P-gp inhibition. J Pharm Pharm Sci. 2017;20:28-37.","journal-title":"J Pharm Pharm Sci"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Madugula N, Neerati P. Influence of toad parotid gland secretion from Indian toad (Bufo melanostictus) in diabetic rats: an experimental evidence of P-glycoprotein inhibition. Int J Pharm Res. 2020;125-135.","DOI":"10.9734\/jpri\/2020\/v32i2030736"}],"container-title":["Turkish Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T12:59:41Z","timestamp":1717678781000},"score":1,"resource":{"primary":{"URL":"https:\/\/turkjps.org\/articles\/doi\/tjps.galenos.2021.47417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,25]]},"published-print":{"date-parts":[[2022,2,25]]}},"URL":"https:\/\/doi.org\/10.4274\/tjps.galenos.2021.47417","relation":{},"ISSN":["1304-530X","2148-6247"],"issn-type":[{"type":"print","value":"1304-530X"},{"type":"electronic","value":"2148-6247"}],"subject":[],"published":{"date-parts":[[2022,2,25]]}}}